drugset / Trial / NCT01207115

A Study of ABT-652 in Adults With Osteoarthritis Pain of the Knee

NCT01207115

Phase 2 Completed 322 enrolled AbbVie
RandomizedParallel-groupDouble-blindTreatment

Summary

To compare the analgesic efficacy and safety of ABT-652 administered twice daily (BID) to placebo in subjects with osteoarthritis (OA) of the knee.

Timeline

Start
2010-09
Primary completion
2011-05
Completion
2011-05

Drugs

EvaluationDrugModalityDoseRoute
Subject ABT-652 Unknown
Comparator Naproxen Small molecule

Indications